Valeant Pharmaceuticals, parent company of Bausch & Lomb and other operations, has reported an overall sales increase of 9 percent to $2.37 billion for the first quarter ended March 31, as compared to the restated turnover for the year-ago period, but the increase was mainly due to new acquisitions. In ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.